GR1803 combination therapy for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called GR1803 combined with another drug (an anti-CD38 antibody) for people with multiple myeloma who have already tried standard treatments. The goal is to see if this combination can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma and have already tried at least one prior treatment that included lenalidomide and a proteasome inhibitor.
- You should be in reasonably good general health, able to carry out daily activities (ECOG 0-2).
- You cannot have received treatment that targets BCMA before.
- You must not have an active infection at the time of the trial.
- You cannot have certain related conditions like plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or amyloidosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This trial tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The goal is to see if it is safe and how it affects the cancer.
This trial tests a new CAR-T cell therapy called GC012F for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this treatment can help control the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.